MedeliX
Start asking

Ulipristal acetate

ellaOne · ATC code G03AD02

Also known as: Ulipristalacetat · Brand names: ellaOne, Lencya, Ulipristal Acetate Hexal, Ulipristal Aristo, Ullionce, Femke, Ulipristalacetat Al, Ulipristalacetat Stada, Ella, Fimelle, Josei, Mahila, Nextelle, Ulpisad

Key facts
Active substance
Ulipristal acetate
Drug class
Postcoital contraceptives
ATC code
G03AD02
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
ellaOne 30 mg tablet · ellaOne 30 mg film-coated tablet
Marketing authorisation holder
Laboratoire HRA Pharma
Information as of
2026-10-27

Key facts

Ulipristal acetate (ellaOne) is a selective progesterone receptor modulator used for emergency contraception. It inhibits or postpones ovulation and is taken after unprotected intercourse or contraceptive failure.

What it is used for

  • Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure
  • Suitable for any woman of child-bearing age, including adolescents

Dosing

  • One 30 mg tablet as soon as possible, no later than 120 hours after the event
  • Can be taken at any time during the menstrual cycle, with or without food
  • Vomiting within 3 hours: take another tablet
  • If the period is late or pregnancy symptoms are present, exclude pregnancy first
  • Renal impairment: no dose adjustment; severe hepatic impairment: not recommended

Contraindications

  • Hypersensitivity to the active substance or any excipient

Important warnings

  • For occasional use only; does not replace a regular contraceptive method
  • Not for use in known or suspected pregnancy; does not prevent pregnancy in every case
  • If the next period is more than 7 days late or pregnancy is suspected, perform a test; consider ectopic pregnancy
  • May reduce the action of hormonal contraception: use a reliable barrier method until the next menstrual period
  • Not recommended in severe asthma treated with oral glucocorticoids

Side effects

  • Most common: headache, nausea, abdominal pain, dysmenorrhea
  • Common also: dizziness, mood disorders, vomiting
  • Hypersensitivity reactions including rash, urticaria, angioedema
  • Somnolence and blurred vision uncommon; ability to drive may be affected

Interactions

  • CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, barbiturates, St John's wort, efavirenz, nevirapine) markedly reduce levels; not recommended after use in the past 4 weeks, consider a copper IUD
  • CYP3A4 inhibitors increase exposure, unlikely to have clinical consequences
  • Hormonal contraceptives: their contraceptive action may be reduced; concomitant use with levonorgestrel emergency contraception is not recommended

Pregnancy and breastfeeding

  • Pregnancy: not intended for use; does not interrupt an existing pregnancy; limited human data do not suggest a safety concern
  • Breast-feeding: excreted in breast milk; breast-feeding not recommended for one week, milk should be expressed and discarded

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • ellaOneLaboratoire HRA Pharma · EMEA/H/C/001027

Source: European Medicines Agency (EMA), product information

Austria

  • LencyaSandoz Gmbh · 1 register entry
  • Ulipristal Acetate HexalHexal Pharma Gmbh · 1 register entry
  • Ulipristal AristoAristo Pharma Gmbh (Art 57) · 1 register entry
  • UllionceStada Arzneimittel Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Germany

  • FemkeExeltis Germany Gmbh · 1 register entry
  • LencyaHexal Ag · 1 register entry
  • Ulipristal AristoAristo Pharma Gmbh (Art 57) · 1 register entry
  • Ulipristalacetat AlAliud Pharma Gmbh · 1 register entry
  • Ulipristalacetat StadaStada Consumer Health Deutschland Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28

Turkey

  • EllaABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • FimelleADEKA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • JoseiBİOFARMA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • MahilaMONTERO İLAÇ VE GIDA SAN. VE TİC. A.Ş. · 1 register entry
  • NextelleBERKO İLAÇ VE KİMYA SAN. A.Ş. · 1 register entry
  • UlpisadSABA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 16 more European countries
Czechia
Ulipristal Acetate Aristo
Denmark
Femke, Ulipristal Acetate Stada
Finland
Femke, Ulipristal Acetate Stada
France
Ulipristal Acetate Biogaran, Ulipristal Acetate Viatris, Ulipristal Acétate Exeltis
Greece
Boled, Elperil
Iceland
Ellaone, Ulipristal Acetate Stada
Ireland
Ulipristal Acetate Rowex
Italy
Evante, Lencya, Ulipristal Aristo
Liechtenstein
Ellaone
Malta
Ecinq
Netherlands
Ecinq, Evante, Femke, Kruidvat Noodanticonceptie Ulipristal, Misstala, Noodanticonceptie Ulipristal Etos, Ulipristal Xiromed, Ulipristalacetaat
Norway
Ellaone, Femke
Poland
Misstala, Ulipristal Aristo
Portugal
Femke, Ulipristal Aristo, Ulipristal Ciclum
Spain
Ulipristal Aristo, Ulipristal Aurovitas, Ulipristal Exeltis, Ulipristal Stada
Sweden
Ulipristal Acetate Stada

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. ellaOne – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/ellaone-epar-product-information_en.pdf
  2. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  4. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  5. Wikidata (CC0): ATC G03AD.

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.